انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
Stephen Strittmatter on a first-in-human trial for treating chronic cervical spinal cord injury
Manage episode 371715912 series 2825528
Stephen Strittmatter (Yale School of Medicine, CT, USA) discusses his first-in-human and randomised trial of a soluble Nogo-receptor-Fc decoy in patients with chronic cervical spinal cord injury. The Article is published in the August issue of The Lancet Neurology.
Read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00215-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laneur
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
177 حلقات
Manage episode 371715912 series 2825528
Stephen Strittmatter (Yale School of Medicine, CT, USA) discusses his first-in-human and randomised trial of a soluble Nogo-receptor-Fc decoy in patients with chronic cervical spinal cord injury. The Article is published in the August issue of The Lancet Neurology.
Read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00215-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laneur
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
177 حلقات
كل الحلقات
×مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.